Daniela Stols-Gonçalves

Dr. Daniela Stols-Gonçalves


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in Trends in Endocrinology & Metabolism
Verified
Journal Article
Closed access
DSDaniela Stols-Gonçalves
Daniela Stols-Gonçalves
GHG. Kees Hovingh
G. Kees Hovingh
MNMax Nieuwdorp
Max Nieuwdorp
AHAdriaan G Holleboom
Adriaan G Holleboom

14 June 2023 in Gut Microbes
Verified
Journal Article
Open access
DSDaniela Stols-Gonçalves
Daniela Stols-Gonçalves
AMAnne Linde Mak
Anne Linde Mak
MMMette S. Madsen
Mette S. Madsen
EVEduard W. J. van der Vossen
Eduard W. J. van der Vossen
EBEveline Bruinstroop
Eveline Bruinstroop
ELEvgeni Levin
Evgeni Levin
Individuals with nonalcoholic fatty liver disease (NAFLD) have an altered gut microbiota composition. Moreover, hepatic DNA methylation may be altered in the state of NAFLD. Using a fecal microbiota transplantation (FMT) intervention, we aimed to investigate whether a change in gut microbiota composition relates to altered liver DNA methylation in NAFLD. Moreover, we assessed whether plasma metabolite profiles altered by FMT relate to changes in liver DNA methylation. Twenty-one individuals with NAFLD underwent three 8-weekly vegan allogenic donor (n = 10) or autologous (n = 11) FMTs. We obtained hepatic DNA methylation profiles from paired liver biopsies of study participants before and after FMTs. We applied a multi-omics machine learning approach to identify changes in the gut microbiome, peripheral blood metabolome and liver DNA methylome, and analyzed cross-omics correlations. Vegan allogenic donor FMT compared to autologous FMT induced distinct differential changes in I) gut microbiota profiles, including increased abundance of Eubacterium siraeum and potential probiotic Blautia wexlerae; II) plasma metabolites, including altered levels of phenylacetylcarnitine (PAC) and phenylacetylglutamine (PAG) both from gut-derived phenylacetic acid, and of several choline-derived long-chain acylcholines; and III) hepatic DNA methylation profiles, most importantly in Threonyl-TRNA Synthetase 1 (TARS) and Zinc finger protein 57 (ZFP57). Multi-omics analysis showed that Gemmiger formicillis and Firmicutes bacterium_CAG_170 positively correlated with both PAC and PAG. E siraeum negatively correlated with DNA methylation of cg16885113 in ZFP57. Alterations in gut microbiota composition by FMT caused widespread changes in plasma metabolites (e.g. PAC, PAG, and choline-derived metabolites) and liver DNA methylation profiles in individuals with NAFLD. These results indicate that FMTs might induce metaorganismal pathway changes, from the gut bacteria to the liver.

16 November 2024 in Cells
Verified
Journal Article
Open access
PDF file
DSDaniela Stols-Gonçalves
Daniela Stols-Gonçalves
AMAbraham S. Meijnikman
Abraham S. Meijnikman
LTLuca Schiliró Tristão
Luca Schiliró Tristão
CSClara Lucato dos Santos
Clara Lucato dos Santos
NDNerissa Denswil
Nerissa Denswil
MNmax Nieuwdorp
max Nieuwdorp
Background: Metabolic dysfunction-associated liver disease (MASLD) and alcohol-associated liver disease (ALD) are among the leading causes of liver disease worldwide. The exact roles of epigenetic factors in both diseases remains largely unknown. In this context, liver DNA methylation remains a field that requires further exploration and understanding. Methods: We performed a systematic review of liver DNA methylation in humans with MASLD or ALD using Ovid MEDLINE, Ovid Embase, and Cochrane Library. We included human studies where liver DNA methylation was assessed in patients with MASLD and/or ALD. The Rayyan platform was used to select studies. Risk of bias was assessed with the “risk of bias in non-randomized studies of interventions” tool, ROBINS-I. We performed pathway analysis using the most important differentially methylated genes selected in each article. Results: Fifteen articles were included in this systematic review. The risk of bias was moderate to serious in all articles and bias due to confounding and patient selection was high. Sixteen common pathways, containing differentially methylated genes, including cancer pathways, were identified in both diseases. Conclusions: There are common pathways, containing differentially methylated genes, in ALD and MASLD, such as pathways in cancer and peroxisome proliferator-activated receptor (PPAR) signaling pathways. In MASLD, the insulin signaling pathway is one of the most important, and in ALD, the MAPK signaling pathway is the most important. Our study adds one more piece to the puzzle of the mechanisms involved in steatotic liver disease.